Medical innovation is about what we can accomplish with patients, said Eleanor Perfetto, Ph.D., M.S., senior vice president of strategic initiatives at the National Health Council during Research!America’s “Medical Innovation 101” Capitol Hill briefing on February 14.
Perfetto moderated the panel of experts who described how different aspects of the research pipeline contribute to the discovery, development and delivery of new treatments for deadly and disabling diseases. They provided recommendations on how to create a more efficient research infrastructure that speeds medical progress.
Keith Yamamoto, Ph.D., vice chancellor for science policy and strategy; vice dean for research at University of California San Francisco and Research!America board member, stressed the essential role of federal funding and collaboration between the public and private sector.
Yamamoto also described precision medicine as a means to improving clinical trials and lowering health care costs while tailoring treatment outcomes for individuals. “We must shift [the] focus from blockbuster drugs to targeted therapies,” he said.
Joe Selby, M.D., MPH, executive director of the Patient-Centered Outcomes Research Institute echoed Yamamoto’s sentiments, adding "One size does not fit all in medication."
Avalon Health Economics LLC’s CEO John Schneider, Ph.D., noted that increased “drug utilization” not only offsets health care costs but it brings clinical and economic value.
The Congressional R&D Caucus joined Research!America in presenting the briefing, which was made possible in part by support from Eli Lilly and Company.